<DOC>
	<DOCNO>NCT00437307</DOCNO>
	<brief_summary>Determination progression free survival 12 month FU Determination total survival , response quality life</brief_summary>
	<brief_title>Hycamtin Plus Carboplatin Versus Established Regimens Treatment Ovarian Cancer Relapse</brief_title>
	<detailed_description>In Germany two establish therapy regime platin sensitive ovarian cancer : combination carboplatin paclitaxel well combination carboplatin gemcitabine . Choice therapy individual due miss randomized comparison regime . Topotecan show good efficacy second-line therapy ovarian cancer well good , especially , non-hematoxic toxicity profile . Several phase II-studies demonstrate synergistic effect topotecan combination carboplatin exhibit good efficacy tolerability . It shall test randomized phase III-study combination topotecan carboplatin show improvement progression-free survival comparison standard regime .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Women ≥18 year age platinumsensitive recurrent ovarian cancer occur least six month completion primary standard therapy eligible Patients measurable assessable lesion CA125 ≥ 2x ULN Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 All patient provide write informed consent Patients two chemotherapy history Progress le six month completion primary standard therapy Simultaneous plan radiation Any known hypersensitivity topotecan , carboplatin , paclitaxel gemcitabine Patients infection Patients pregnant breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>